AHK-Cu vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- Hours (topical, variable by formulation)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical, Scalp application, Subcutaneous (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.1% concentration
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Stimulates hair follicle growth and reduces shedding
- Increases dermal papilla cell proliferation
- Promotes wound healing and skin regeneration
- Antioxidant protection via superoxide dismutase activation
- Improves skin elasticity and firmness
- Supports collagen and elastin production
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Generally well-tolerated topically
- Mild scalp irritation or redness in sensitive individuals
- Possible temporary hair shedding phase at treatment initiation
- Copper accumulation with excessive systemic use (rare)
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —